Mainstream

Royalty Pharma Targets $3b Share Buyback And Projects 4 9% Growth In 2025 Portfolio Receipts

Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts

Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts

Post ContentrprxRead More

You might also be interested in reading Moody’s, Elliptic join forces for enhanced VASP risk screening.

February 11, 2025
In Mainstream